Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/28283
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Carlino, Matteo S | - |
dc.contributor.author | Menzies, Alexander M | - |
dc.contributor.author | Atkinson, Victoria | - |
dc.contributor.author | Cebon, Jonathan S | - |
dc.contributor.author | Jameson, Michael B | - |
dc.contributor.author | Fitzharris, Bernard M | - |
dc.contributor.author | McNeil, Catriona M | - |
dc.contributor.author | Hill, Andrew G | - |
dc.contributor.author | Ribas, Antoni | - |
dc.contributor.author | Atkins, Michael B | - |
dc.contributor.author | Thompson, John A | - |
dc.contributor.author | Hwu, Wen-Jen | - |
dc.contributor.author | Hodi, F Stephen | - |
dc.contributor.author | Guminski, Alexander D | - |
dc.contributor.author | Kefford, Richard | - |
dc.contributor.author | Wu, Haiyan | - |
dc.contributor.author | Ibrahim, Nageatte | - |
dc.contributor.author | Homet Moreno, Blanca | - |
dc.contributor.author | Long, Georgina V | - |
dc.date | 2020-06-30 | - |
dc.date.accessioned | 2021-12-07T02:51:45Z | - |
dc.date.available | 2021-12-07T02:51:45Z | - |
dc.date.issued | 2020-10-01 | - |
dc.identifier.citation | Clinical Cancer Research 2020; 26(19): 5086-5091 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/28283 | - |
dc.description.abstract | Combination therapy with reduced-dose programmed death 1 inhibitor plus standard-dose cytotoxic T-lymphocyte-associated antigen 4 inhibitor demonstrated efficacy, but substantial toxicity, in melanoma. We present long-term results of part 1B of KEYNOTE-029, which assessed safety and efficacy of standard-dose pembrolizumab plus reduced-dose ipilimumab in advanced melanoma. Part 1B was an expansion cohort of the open-label, phase Ib portion of KEYNOTE-029. Eligible patients had advanced melanoma and no previous immune checkpoint inhibitor therapy. Patients received pembrolizumab 2 mg/kg (amended to 200 mg) every 3 weeks plus ipilimumab 1 mg/kg every 3 weeks (four cycles), then pembrolizumab alone for up to 2 years. Primary end point was safety; secondary end points included objective response rate (ORR), progression-free survival (PFS), duration of response (DOR), and overall survival (OS). A total of 153 patients received at least one dose of pembrolizumab plus ipilimumab. At a median follow-up of 36.8 months, 71.9% had received four doses of ipilimumab and 30.7% had completed 2 years of pembrolizumab; 26.1% completed both treatments. Treatment-related adverse events occurred in 96.1% (47.1% grade 3/4; no deaths), leading to discontinuation of one or both study drugs in 35.9%. ORR was 62.1% with 42 (27.5%) complete and 53 (34.6%) partial responses. Median DOR was not reached; 36-month ongoing response rate was 84.2%. Median PFS and OS were not reached; 36-month rates were 59.1% and 73.4%, respectively. Standard-dose pembrolizumab plus reduced-dose ipilimumab demonstrated robust antitumor activity, durable response, and favorable long-term survival with manageable toxicity. | en |
dc.language.iso | eng | |
dc.title | Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Clinical Cancer Research | en |
dc.identifier.affiliation | Department of Clinical Medicine, Macquarie University, Macquarie Park, New South Wales, Australia | en |
dc.identifier.affiliation | Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia | en |
dc.identifier.affiliation | Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | Department of Medicine, Blacktown Hospital, Blacktown, New South Wales, Australia | en |
dc.identifier.affiliation | Department of Medicine, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | Department of Medical Oncology, Gallipoli Medical Research Foundation, Greenslopes Private Hospital, University of Queensland, Greenslopes, Queensland, Australia | en |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute | en |
dc.identifier.affiliation | School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Medical Oncology | en |
dc.identifier.affiliation | Department of Medical Oncology, Tasman Health Care, Gold Coast University Hospital, Southport, Queensland, Australia | en |
dc.identifier.affiliation | Regional Cancer Centre, Waikato Hospital, and Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand | en |
dc.identifier.affiliation | Canterbury Regional Cancer & Haematology Service, Christchurch Hospital, Christchurch, New Zealand | en |
dc.identifier.affiliation | Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California | en |
dc.identifier.affiliation | Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC | en |
dc.identifier.affiliation | Department of Medicine, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington | en |
dc.identifier.affiliation | Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas | en |
dc.identifier.affiliation | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts | en |
dc.identifier.affiliation | Department of Clinical Oncology, MSD China, Beijing, China | en |
dc.identifier.affiliation | Department of Clinical Oncology, Merck & Co., Inc., Kenilworth, New Jersey | en |
dc.identifier.affiliation | Clinical Haematology | en |
dc.identifier.doi | 10.1158/1078-0432.CCR-20-0177 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0002-3898-950X | en |
dc.identifier.orcid | 0000-0001-7068-4311 | en |
dc.identifier.orcid | 0000-0002-3732-766X | en |
dc.identifier.orcid | 0000-0003-0794-949X | en |
dc.identifier.orcid | 0000-0001-8894-3545 | en |
dc.identifier.pubmedid | 32605909 | |
local.name.researcher | Cebon, Jonathan S | |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.